JPMorgan lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $20 from $37 and keeps a Neutral rating on the shares. The firm updated its model and lowered its price target following top-line results from the phase 3 RISE UP trial for Pyrukynd in sickle cell disease. The firm also made adjustments to its longer-term expense assumptions and its revenue builds for mitapivat in pyruvate kinase deficiency and mitapivat in thalassemia.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs
- Leerink upgrades Agios to Outperform after 51% pullback
- Agios Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
- Agios Pharmaceuticals price target lowered to $32 from $54 at BofA
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!